{"name":"Vical","slug":"vical","ticker":"","exchange":"","domain":"","description":"Vical is a biotechnology company focused on the discovery and development of therapeutic and preventive vaccines and other treatments for serious diseases. The company has a diverse pipeline with several candidates in various stages of clinical development, including a Phase 3 program for Allovectin-7 in melanoma.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1622000,"revenueGrowth":1208.1,"grossMargin":0,"rdSpend":3182000,"netIncome":-5694000,"cash":11586000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"allovectin-7","genericName":"allovectin-7","slug":"allovectin-7","indication":"Metastatic melanoma","status":"phase_3"},{"name":"allovectin-7/dacarbazine","genericName":"allovectin-7/dacarbazine","slug":"allovectin-7-dacarbazine","indication":"Metastatic melanoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Leuvectin","genericName":"Leuvectin","slug":"leuvectin","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Leuvectin","genericName":"Leuvectin","slug":"leuvectin","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"allovectin-7","genericName":"allovectin-7","slug":"allovectin-7","phase":"phase_3","mechanism":"Allovectin-7 is a DNA-based immunotherapy that delivers the HLA-B7 and β2-microglobulin genes directly into tumor cells to enhance immune recognition and rejection.","indications":["Metastatic melanoma","Cutaneous T-cell lymphoma (mycosis fungoides)"],"catalyst":""},{"name":"allovectin-7/dacarbazine","genericName":"allovectin-7/dacarbazine","slug":"allovectin-7-dacarbazine","phase":"phase_3","mechanism":"Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication.","indications":["Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE92WUFNNmlueVZSa3NRSFF0VmZ3NEVOYV9OVnI0TmZkdUpBMDJWUVNwdi1jTU9Eem1tZl8yN0g3aHZZdzk4cjJhaFBfOGZBVjVEWDFDdGduTQ?oc=5","date":"2026-03-17","type":"pipeline","source":"American Academy of Arts and Sciences","summary":"David C. Kaslow - American Academy of Arts and Sciences","headline":"David C. Kaslow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPR0dzTG9uempFSUtaWEFTckI2Q1d6djR4dEhVYkFITVZEU0U2Y3JxRFJKZ3NfeHdCVVJ6SkplS3VHNjlhVllYVXltSUQ0bG1XWU54dHlLY2NOVm5HR05tekFVX25fT3REOE43X1lGYWZPQTNtS1hkejV6cVpGOFlHRXVrVnBveXpoQTByOXUyMkYzdnYwR09zcHNZRC16ajBrYUtWSkV6NHNQUklTend0VzZlM0lWMloteXkwUXRiMA?oc=5","date":"2025-09-09","type":"pipeline","source":"ION Analytics","summary":"GL Capital raises continuation vehicle for China’s SciClone Pharmaceuticals - ION Analytics","headline":"GL Capital raises continuation vehicle for China’s SciClone Pharmaceuticals","sentiment":"neutral"},{"date":"2024-05-08","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SCHEDULE 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"2024-03-15","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2024-03-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-02-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNc0JuMjZnMFNla3NzQkgxM0s3TkU5c3lJU29PZ3NVVDlmdjdLdjkwcC1COWUzUFNNNW9hakt3ZmxtSWl2OWJVai1xUFQ3Umxub3hsVWRHZFB1NDluVXBPZTZTRGNrYXBINUFZclRlcVJ4ZTBmSTQtOVRwZDJIWmpaNmRRNk1ySFFyRjhVZXNjVkdBaWswRzFlNEdGczA5TUVxdGR6M2c5TQ?oc=5","date":"2020-05-17","type":"trial","source":"Healthcare Digital","summary":"Abbott inks pact with Astellas Pharma in Phase 3 clinical trial for ASP0113 - Healthcare Digital","headline":"Abbott inks pact with Astellas Pharma in Phase 3 clinical trial for ASP0113","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOXzBOcG5FMVQ5NFhrRExDNmpaaXFKTXNPN2ZWR1ZoOTRFS2xDRzRhRFUyOHNSczAtZHNHM2d1QlktVnhuUnFjc3REMFJpT1lZbDJTbFplcnd5S0o3R1d4dDNuejd4M3Fkd1d4TUJoeV9QTVJFRVBmcEY4M2stVm5wWnV0RVpnbjVYak1aS1A3T2VqbVkyUnJ3X2c0YjdQR211ckVOLU5rRHlnMFNJV1NBSUhEdnJtUUk?oc=5","date":"2019-06-03","type":"deal","source":"GlobeNewswire","summary":"Vical and Brickell Announce Merger Agreement - GlobeNewswire","headline":"Vical and Brickell Announce Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5jemliTkQ2SS1PZTlDbGRSRWc5Q05HaDJKTWpDcF90YTJiYWlMWXdWLTE3ZTMzeTAwWVlHR3c4VERvWEtRUTB6ZmFYYzVYSlBnX1ktVkN5bHctcXVNTnBwal9Kcl9BR28yU3Bheg?oc=5","date":"2019-06-03","type":"deal","source":"BioSpace","summary":"Vical and Brickell to Merge in All-Stock Deal - BioSpace","headline":"Vical and Brickell to Merge in All-Stock Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOeUFUbDl2R0dMVEY5NWlHeTVOb0Q3ay1fMFB5WmVXQURQem9YektURGVZNEpFMnNzZnB3MnVaWGV0TDZ5VS1ZeXNvZ1FXcWVqOFdkc1E1VWlqdlVtcUd5X01NNUlRTk1LcWpDTTZRVzl3M2JsY3FqaUhNWU9sb0lQNVMzV1dOOE40RFE?oc=5","date":"2018-06-11","type":"pipeline","source":"BioPharma Dive","summary":"Vical abandons herpes vaccine after mid-stage miss - BioPharma Dive","headline":"Vical abandons herpes vaccine after mid-stage miss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNa2dacVhvdjAxZmZzMWtpU25fWmRCU0dsTmZhcFIxREJKejgwdjItWVNINXhYLW9CV1c1OWVrdFB5ZTFWY1Z0aTVWcjBRV3ZLWEgtdHhEbGlDWXFBdVNLcG5VbmhNeU9uN00tM1JEb1V2ZFVMRms1ZjJUT3JMRGtsV0QyRzI3eC1XUXJuVlkyYS03Qi1BWUpyM1Zmd0RJZWdnVXhpalVDaUlHR2E5WThGZGtOdw?oc=5","date":"2018-06-11","type":"trial","source":"Genetic Engineering and Biotechnology News","summary":"Vical Halts Development of HSV-2 Vaccine after Phase II Failure - Genetic Engineering and Biotechnology News","headline":"Vical Halts Development of HSV-2 Vaccine after Phase II Failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQRnFQQ2pRSnRhRlRoYnp3ek0tenBlakhiX1hoeUZoUjRnVGJ2bm1aZG1WdS1zZ1gtcl9zWEZvcW1TSWxjUDI1czIzU05kQkFKcnlaQllkWHNzY2k1SGlzUy1YZlg1YU5PYl9ncU9XMVk2TVFUa0dOVWJZS1BZbUhaWjBaNkFjTkc4bUNzSXBqSjVJa2ZMNGJaajZLV3pjVjZv?oc=5","date":"2018-06-11","type":"pipeline","source":"Fierce Biotech","summary":"More bad news for Vical as it abandons herpes vaccine program - Fierce Biotech","headline":"More bad news for Vical as it abandons herpes vaccine program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOY3F6cVc4N2JtekFjRVNibVZPWDVJeFh4VUpLMHZIMExoREtwOHBwM3lDQk1zQTFMYXYyYnNUb2cwLTZ5aDRzNnd1SFRac0dlbUdERWVSTVZ0SVg4QlRtSGRXVXI5OGJQT1pUMEtoYUs1djBGX2RaVXM2N0VPTlo3b2RubldvYlV2aEVvSkFLaVZURTFidm85T1BKSXo1dw?oc=5","date":"2018-01-31","type":"pipeline","source":"Fierce Biotech","summary":"After years of setbacks, Vical to slash jobs, Astellas drug work - Fierce Biotech","headline":"After years of setbacks, Vical to slash jobs, Astellas drug work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOU0sybEZNUmJ6ZXpVekxkLUhGTjFyNWthNGpOb1ZaZ2J4ejFaOUhGYWdYcE5YT1IwUUYtZUptVV9Pd2h5b0Q1QzY4dmRHTnJuZGt3eHlOR3NvV1pmZ0NGc0FXRWE0a01tWW92RXFJMjVqM2xfTWczREQyaXBFYmdWTXZpQzBmeW5Nc1hpdE5HdGx5QkJkUWkwS3F3cktBT1VkeWZ3WkM0OXA?oc=5","date":"2018-01-24","type":"trial","source":"Clinical Trials Arena","summary":"Astellas’ cytomegalovirus vaccine fails to meet Phase III endpoints - Clinical Trials Arena","headline":"Astellas’ cytomegalovirus vaccine fails to meet Phase III endpoints","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPSGxjdDdzdmczbjdzS3h4OEtSdl9ZaG9MUzdXRHU0dVc4ZUNBekNsWjgyVFNJY2Z6aGoxLUpaUThXN1hNT2dxWHBiVHJUazg4Z0V6ejhpbnJjQVVNMHZJWXlZeS1vbTFKZ29JRG5TblluVzZtSHFKNHJ3SGozR3E2MnpoN1UydFFDcmRUNmtBWFNfR2FDR2c?oc=5","date":"2018-01-23","type":"trial","source":"BioPharma Dive","summary":"Astellas, Vical’s CMV vaccine comes up short in Phase 3 - BioPharma Dive","headline":"Astellas, Vical’s CMV vaccine comes up short in Phase 3","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"discontinued":1,"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":1622000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":1622000,"period":"2018-12-31"},{"value":124000,"period":"2018-12-31"},{"value":47000,"period":"2018-09-30"},{"value":735000,"period":"2018-06-30"},{"value":716000,"period":"2018-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":3182000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5694000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":11586000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}